LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microbiologics and Microbix Partner on Viral Controls for Diagnostics

By LabMedica International staff writers
Posted on 12 Apr 2015
Image: Under a new partnership, inactivated viruses from Microbix Biosystems, Inc. will be incorporated into a line of full process controls under Microbiologics’ Helix Elite Molecular Standards brand as well as instrument-specific quality control sets (Photo courtesy of Microbiologics).
Image: Under a new partnership, inactivated viruses from Microbix Biosystems, Inc. will be incorporated into a line of full process controls under Microbiologics’ Helix Elite Molecular Standards brand as well as instrument-specific quality control sets (Photo courtesy of Microbiologics).
Microbiologics, Inc. (St. Cloud, MN, USA) has entered into an agreement to source inactivated viruses from Microbix Biosystems, Inc. (Mississauga, ON, Canada) to be incorporated into a line of full process controls under Microbiologics’ Helix Elite Molecular Standards brand as well as instrument-specific quality control sets.

Diagnostic assays are dependent on controls to demonstrate test performance characteristics and staff proficiency, but laboratories struggle to identify adequate biomaterials and frequently use clinical samples that may not be well characterized or consistently available. Increased regulation requires that labs more carefully consider the source, quality, and format of their molecular and culture-based control materials. This partnership will combine both companies’ expertise in biomaterial development, preservation, and distribution to create highly stable viral controls for molecular testing.

“We are pleased to use Microbix materials in Microbiologics products as they have a strong, global reputation for high-quality viral preparations for the vaccine and immunodiagnostics markets” Brian Beck, PhD, vice president, Molecular Products and Services, Microbiologics, “Incorporation of Microbix viral materials into our lyophilized, molecular-compatible formats complements our existing synthetic standards and extends our catalog to include extraction controls for gastrointestinal, respiratory, blood borne, and sexually transmitted viral pathogens.”

Phil Casselli, senior vice president, Business Development, Microbix, said, “We are pursuing a multipronged approach to exploit the high-growth molecular diagnostics marketplace. Microbiologics has relationships with instrument manufacturers, as well as large-scale distribution capabilities, making them an ideal partner to help expand the reach of our developing molecular program. Our unique isolates offering complements Microbiologics’ strengths. We will both be focused on what we do best in this relationship.”

“As part of our commitment to a safer, healthier world, Microbiologics continues to partner with industry leaders such as Microbix to develop advanced, practical controls that support the evolving field of molecular microbiology,” said Brad Goskowicz, Microbiologics’ CEO, “We look forward to working with molecular diagnostic manufacturers to ensure that clinical laboratories have the appropriate and highest quality control material for their instruments and assays.”

Related Links:
Microbiologics
Microbix Biosystems
Helix Elite, CE-marked IVD molecular standards

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more